Excerpt

To understand better the health economic issues that may arise in the course of integrating genomic data into health care, the Roundtable on Translating Genomic-Based Research for Health hosted a workshop in Washington, DC, on July 17-18, 2012, that brought together economists, regulators, payers, biomedical researchers, patients, providers, and other stakeholders to discuss the many factors that may influence this implementation. The workshop was one of a series that the roundtable has held on this topic, but it was the first focused specifically on economic issues.

Contents

• THE NATIONAL ACADEMIES
• PLANNING COMMITTEE
• ROUNDTABLE ON TRANSLATING GENOMIC-BASED RESEARCH FOR HEALTH
• Reviewers
• Acknowledgments
• Figure, Tables, and Box
• Abbreviations and Acronyms
• 1. Introduction and Overview
  • ORGANIZATION OF THE WORKSHOP
  • MAJOR THEMES OF THE WORKSHOP
• 2. Genomics, Population Health, and Technology
  • THE VALUE OF GENOMIC DATA
  • THE LONG-TERM AND MID-TERM PROMISES OF GENOMICS
  • GENOMIC DATA IN HEALTHY PEOPLE
  • CHALLENGES TO IMPLEMENTATION
  • ANOTHER MEDICAL TEST
• 3. The Intersection of Genomics and Health Economics
  • ECONOMIC EVALUATION TOOLS
  • INCREMENTAL COST-EFFECTIVENESS RATIOS
  • GENOME SEQUENCING
  • COMPARATIVE-EFFECTIVENESS RESEARCH
  • THREE CHALLENGES
• 4. Preconception Care and Sequencing
  • A CLINICIAN’S PERSPECTIVE
  • A FUTURIST’S PERSPECTIVE
  • A PATIENT’S PERSPECTIVE
  • ECONOMIC PERSPECTIVES
  • DISCUSSION
• 5. Unprovoked Deep Vein Thrombosis
  • A CLINICIAN’S PERSPECTIVE
  • A FUTURIST’S PERSPECTIVE
  • A PATIENT’S PERSPECTIVE
  • ECONOMIC PERSPECTIVES
  • DISCUSSION
• 6. Cancer Care
  • A CLINICIAN’S PERSPECTIVE
  • A FUTURIST’S PERSPECTIVE
  • A PATIENT’S PERSPECTIVE
  • ECONOMIC PERSPECTIVES
  • DISCUSSION
• 7. Panelists’ and Stakeholders’ Perspectives
  • A CLINICIAN’S PERSPECTIVE
  • A RESEARCHER’S PERSPECTIVE
  • A CHIEF SCIENTIFIC OFFICER’S PERSPECTIVE
  • A PATIENT’S PERSPECTIVE
  • A PUBLIC HEALTH OFFICER’S PERSPECTIVE
  • A HOSPITAL ADMINISTRATOR’S PERSPECTIVE
  • ECONOMIC PERSPECTIVES
  • ADDITIONAL ISSUES
  • CLOSING REMARKS

Rapporteurs: Adam C. Berger and Steve Olson

This project was supported by contracts between the National Academy of Sciences and the American Academy of Nursing (unnumbered contract); American College of Medical Genetics and Genomics (unnumbered contract); American Heart Association (unnumbered contract); American Medical Association (unnumbered contract); American Society of Human Genetics (unnumbered contract); Blue Cross and Blue Shield Association (unnumbered contract); Centers for Disease Control and Prevention (Contract No. 200-2011-38807); College of American Pathologists (unnumbered contract); Department of the Air Force (Contract No. FA7014-10-P-0072); Department of Veterans Affairs (Contract No. V101(93) P-2238); Eli Lilly and Company (Contract No. LRL-0028-07); Genetic Alliance (unnumbered contract); Health Resources and Services Administration (Contract No. HHSH250201100119P); Johnson & Johnson (unnumbered contract); The Kaiser Permanente Program Offices Community Benefit II at the East Bay Community Foundation (Contract No. 20121257); Life Technologies (unnumbered contract); National Cancer Institute (Contract No. N01-OD-4-2139, TO#189); National Coalition for Health Professional Education in Genetics (unnumbered contract); National Heart, Lung, and Blood Institute (Contract No. N01-OD-4-2139, TO#275); National Human Genome Research Institute (Contract No. N01-OD-4-2139, TO#264 and Contract No. HHSN263201200074I, TO#5); National Institute of Mental Health (Contract No. N01-OD-4-2139, TO#275); National Institute on Aging (Contract No. N01-OD-4-2139, TO#275); National Society of Genetic Counselors (unnumbered contract); Northrop Grumman Health IT (unnumbered contract); Office of Rare Diseases Research (Contract No. N01-OD-4-2139, TO#275); and Pfizer Inc. (Contract No. 140-N-1818071). Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the views of the organizations or agencies that provided support for the project.

Suggested citation:

IOM (Institute of Medicine). 2013. The economics of genomic medicine: Workshop summary. Washington, DC: The National Academies Press.

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.